Double maintains 3 strategies that include ROIV - Roivant Sciences Ltd.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CANE | 0.18% | $11.26M | 0.29% |
| CARY | 0.19% | $347.36M | 0.8% |
| SGOV | 0.19% | $50.43B | 0.09% |
| UUP | 0.32% | $198.33M | 0.77% |
| STOT | 0.41% | $252.89M | 0.45% |
| BSCP | 0.44% | $3.25B | 0.1% |
| IBTJ | 0.50% | $682.49M | 0.07% |
| IBTK | 0.70% | $446.70M | 0.07% |
| UDN | 0.79% | $147.89M | 0.78% |
| STPZ | -0.86% | $443.02M | 0.2% |
| FXE | -0.88% | $585.58M | 0.4% |
| IBDQ | 0.91% | $2.96B | 0.1% |
| IBTI | -1.04% | $1.06B | 0.07% |
| PSQA | 1.13% | $36.46M | 0.2% |
| IEI | 1.23% | $15.58B | 0.15% |
| IBTF | 1.23% | $1.98B | 0.07% |
| LDUR | -1.41% | $922.21M | 0.5% |
| CTA | -1.49% | $1.06B | 0.76% |
| BUXX | 1.90% | $312.37M | 0.25% |
| TBIL | -1.90% | $5.76B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -45.08% | $185.99M | 0.85% |
| TAIL | -44.00% | $95.09M | 0.59% |
| BTAL | -36.97% | $312.42M | 1.43% |
| IVOL | -16.96% | $342.02M | 1.02% |
| XHLF | -13.90% | $1.73B | 0.03% |
| TFLO | -12.75% | $6.74B | 0.15% |
| KCCA | -12.10% | $108.82M | 0.87% |
| FTSD | -12.01% | $233.04M | 0.25% |
| FXY | -10.51% | $812.67M | 0.4% |
| ULST | -10.06% | $595.49M | 0.2% |
| TBLL | -9.98% | $2.12B | 0.08% |
| XONE | -9.79% | $627.68M | 0.03% |
| BIL | -9.09% | $41.97B | 0.1356% |
| BILS | -8.99% | $3.80B | 0.1356% |
| TPMN | -7.69% | $30.94M | 0.65% |
| SPTS | -6.84% | $5.77B | 0.03% |
| SCHO | -6.06% | $11.00B | 0.03% |
| IBTG | -5.39% | $1.92B | 0.07% |
| GBIL | -4.93% | $6.35B | 0.12% |
| SHYM | -4.49% | $355.63M | 0.35% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VSA | -7.95% | $8.76M | -15.57% | 0.00% |
| CBOE | -6.97% | $24.35B | +37.95% | 1.09% |
| STG | -6.34% | $31.09M | -22.74% | 0.00% |
| DFDV | -5.38% | $298.06M | +2,070.86% | 0.00% |
| LITB | -4.57% | $23.17M | -74.54% | 0.00% |
| PSQH | -4.50% | $101.55M | -38.06% | 0.00% |
| CARV | -3.89% | $8.88M | +17.45% | 0.00% |
| RRGB | -3.16% | $112.98M | +4.43% | 0.00% |
| UUU | -3.14% | $8.42M | +150.90% | 0.00% |
| K | -2.68% | $27.53B | +40.77% | 2.87% |
| NEUE | -2.23% | $60.98M | +32.62% | 0.00% |
| CCRN | -1.98% | $418.97M | -3.84% | 0.00% |
| AGL | -1.92% | $989.35M | -58.43% | 0.00% |
| ZCMD | -1.20% | $30.81M | +2.52% | 0.00% |
| TU | -0.70% | $25.24B | +7.19% | 6.97% |
| FUBO | -0.58% | $1.23B | +191.13% | 0.00% |
| HUSA | -0.46% | $18.72M | -18.25% | 0.00% |
| LTM | -0.37% | $12.62B | -95.43% | 2.40% |
| MO | -0.37% | $100.29B | +27.49% | 6.88% |
| OCFT | -0.21% | $272.27M | +313.41% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 69.99% | $4.90B | 0.35% |
| IBB | 66.43% | $5.44B | 0.45% |
| BBH | 60.56% | $340.09M | 0.35% |
| FBT | 60.16% | $1.02B | 0.54% |
| GNOM | 58.99% | $46.32M | 0.5% |
| PBE | 58.98% | $228.63M | 0.58% |
| PTH | 57.72% | $97.73M | 0.6% |
| XT | 57.52% | $3.46B | 0.46% |
| QQQJ | 57.19% | $630.82M | 0.15% |
| CGBL | 57.16% | $2.59B | 0.33% |
| VT | 56.94% | $49.16B | 0.06% |
| URTH | 56.80% | $5.14B | 0.24% |
| DUHP | 56.72% | $8.84B | 0.21% |
| SUSA | 56.66% | $3.60B | 0.25% |
| ACWI | 56.57% | $22.46B | 0.32% |
| USPX | 56.54% | $1.28B | 0.03% |
| PINK | 56.53% | $130.93M | 0.5% |
| ITOT | 56.40% | $71.88B | 0.03% |
| SPGM | 56.37% | $1.10B | 0.09% |
| FQAL | 56.31% | $1.05B | 0.16% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IMVT | 62.26% | $2.89B | -43.13% | 0.00% |
| ACLX | 53.70% | $3.67B | +16.69% | 0.00% |
| BN | 52.34% | $103.50B | +46.08% | 0.54% |
| CRNX | 52.31% | $2.75B | -39.10% | 0.00% |
| CRH | 51.61% | $63.98B | +24.72% | 0.39% |
| KRYS | 50.92% | $4.14B | -25.96% | 0.00% |
| BNT | 50.74% | $12.62B | +46.50% | 0.00% |
| CGON | 50.00% | $1.98B | -19.15% | 0.00% |
| OCUL | 49.91% | $1.58B | +53.80% | 0.00% |
| MFA | 49.63% | $987.52M | -9.59% | 14.71% |
| DYN | 49.32% | $1.16B | -77.45% | 0.00% |
| DNLI | 48.76% | $2.08B | -31.63% | 0.00% |
| NDSN | 48.58% | $12.52B | -1.56% | 1.40% |
| RNA | 48.44% | $3.53B | -27.55% | 0.00% |
| RITM | 48.42% | $6.18B | +9.08% | 8.55% |
| IDYA | 48.38% | $1.88B | -44.46% | 0.00% |
| AMKR | 48.09% | $5.46B | -46.50% | 1.47% |
| LGND | 48.05% | $2.22B | +25.53% | 0.00% |
| NCV | 48.05% | - | - | 6.47% |
| NUVL | 48.00% | $5.66B | +6.98% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EXC | 0.10% | $43.41B | +24.89% | 3.62% |
| PRPO | 0.11% | $23.92M | +231.66% | 0.00% |
| AWK | 0.12% | $27.50B | +7.88% | 2.23% |
| VHC | -0.16% | $57.60M | +131.12% | 0.00% |
| DG | 0.16% | $24.80B | -12.33% | 2.62% |
| OCFT | -0.21% | $272.27M | +313.41% | 0.00% |
| KR | 0.26% | $46.11B | +34.48% | 1.84% |
| MSEX | 0.34% | $982.21M | +2.01% | 2.46% |
| VSTA | 0.35% | $332.04M | +38.00% | 0.00% |
| MCK | 0.36% | $90.44B | +23.40% | 0.39% |
| MO | -0.37% | $100.29B | +27.49% | 6.88% |
| LTM | -0.37% | $12.62B | -95.43% | 2.40% |
| HAIN | 0.37% | $146.21M | -76.52% | 0.00% |
| HUSA | -0.46% | $18.72M | -18.25% | 0.00% |
| FUBO | -0.58% | $1.23B | +191.13% | 0.00% |
| TU | -0.70% | $25.24B | +7.19% | 6.97% |
| OXBR | 0.83% | $15.78M | -4.50% | 0.00% |
| CPSH | 1.13% | $38.93M | +59.05% | 0.00% |
| ZCMD | -1.20% | $30.81M | +2.52% | 0.00% |
| CYCN | 1.20% | $10.08M | +36.52% | 0.00% |
SeekingAlpha
Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle
Yahoo
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetic/PK data for inhaled mosliciguat in healthy male volunteers. The peer-reviewed manuscript, titled “Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized […]
SeekingAlpha
Greenlight Capital outperforms with an 8.2% Q1 2025 return. Check out the major stake increases and selective trims in the portfolio.
Finnhub
Brepocitinib: Investor Event Seeking to improve the lives of patients with DM and other serious autoimmune conditions June 17, 2025 ...
Finnhub
WALTHAM - Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulmonary diseases and a Roivant ...
SeekingAlpha
The fund outperformed the benchmark during the last quarter. From a sector perspective, Energy was at the forefront of index returns as global oil prices rallied.
Current Value
$10.921 Year Return
Current Value
$10.921 Year Return
